Thigh muscle mass is associated with circulating valeric acid in healthy male	1
volunteers	2
	3
Running title:	4
Muscle mass and circulating valeric acid in males	5
	6
Eva M. Hassler ¹ , Gernot Reishofer ^{2,5} , Harald Köfeler ³ , Wilfried Renner ⁴ , Hannes Deutschmann H ¹ , Harald Mangge ^{4,5} , Markus Herrmann ⁴ , Stefan L. Leber ¹ , Felix Gunzer ¹ , Gunter Almer ⁴	7 8
¹ Division of Neuroradiology, Vascular and Interventional Radiology; Department of Radiology	9 10
Medical University Graz, 8036 Graz, Austria	11
² Department of Radiology, Medical University Graz, 8036 Graz, Austria	12
³ Core Facility Mass Spectrometry, Center for Medical Research, Medical University Graz, 8036 Graz, Austria	13 14
⁴ Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University Graz, 8036 Graz, Austria	15 16
⁵ BiotechMed Graz, 8010 Graz, Austria	17
	18
Corresponding Author:	19
Gunter Almer	20
Clinical Institute of Medical and Chemical Laboratory Diagnostics,	21
Medical University Graz, Auenbruggerplatz, A-8036 Graz	22
Email: <u>gunter.almer@medunigraz.at</u>	23
	24
Submission includes supplementary material.	25
	26
	27

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Abstract:

46

Short-chain fatty acids (SCFAs) are circulating metabolites generated by gut microbiota. Recently, a	30
link between age-related muscle loss and gut microbiota has been described, and SCFAs could play a	31
mediating role in this relationship. Acetic, propionic, and butyric acid are the abundant forms and are	32
considered to have health benefits, less is known about valeric and caproic acid.	33
In a cross-sectional study including 155 healthy volunteers, we investigated the relationship between	34
muscle area, as well as intramuscular adipose tissue measured by magnet resonance imaging and	35
circulating SCFAs. SCFAs and additional parameters were measured from serum and sport activities	36
recorded by means of a questionnaire.	37
We found a significant positive association between valeric acid (VA) levels and the thigh cross-	38
sectional muscle area in males. This relationship was independent of age, BMI and weekly training	39
times and was not observed in females. No associations between other SCFAs and the thigh muscle	40
cross-sectional area were observed.	41
To our knowledge, this is the first human study demonstrating a significant relationship between thigh	42
muscle mass and VA, supporting the thesis of the "gut-muscle axis" with VA as a possible interacting	43
player, on the one hand, affected by sex differences, on the other.	44
	45

Word count: 4115

Keywords: Valeric acid, short-chain fat	ty acids, magnet resonance imaging, muscle mass	47
Abbreviations:		48
CA	caproic acid (C6)	49
FFA	free fatty acids	50
GC-EI/MS	gas chromatograph-electron impact-mass spectrometer	51

ΙΜΑΤ	intramuscular adipose tissue	52
МА	muscle area	53
MRI	magnet resonance imaging	54
МТВЕ	methyl tert-butyl ether	55
SCFA	short-chain fatty acids	56
SMA	spinal muscular atrophy	57
SMN	survival motoneuron	58
VA	valeric acid (C5)	59

Introduction

A balanced diet and regular exercise are the cornerstones of a healthy lifestyle and still the best 62 protection against numerous diseases on a worldwide rise, such as cardiovascular (e.g. strokes and 63 heart attacks) or metabolic diseases (e.g. type 2 diabetes) (1, 2). In recent years, clinicians have also 64 recognized the importance of the gut microbiome as a metabolical key player, as well as its close 65 relationship with obesity and related cardiometabolic disorders, specifically when the microbiome is 66 out of balance (3, 4).

One of the main groups of metabolites produced by the gut microbiome are short-chain fatty acids 68 (SCFAs). The main origin of all SCFAs is the gut, where they are produced in the large intestine by colon 69 microbiota fermenting indigestible food components such as fibers like complex carbohydrates and 70 resistant starch (5, 6). They are later metabolized in colonic epithelial cells, liver and other tissues, to 71 serve as an energy source for the body, including the muscles (7). The three most common SCFAs are 72 acetate, propionate, and butyrate (8). All three were found to have diverse physiological functions, for 73 instance, affecting the blood lipid profiles, vitamin concentrations and energy production (9) as well as 74 appetite, cardiometabolic health maintenance (10) and insulin sensitivity (11). Therefore, they are not 75 only important for intestinal health (12), but because they enter the systemic circulation, they affect 76 metabolism and peripheral tissue functions. Furthermore, they can alter dendritic cell and macrophage 77 function to reduce the production of pro-inflammatory cytokines and they are also involved in the 78 regulation of glycemic responses and triglyceride metabolism (6, 7). 79

SCFAs are very soluble and are absorbed easily from the intestinal lumen into the blood circulation via 80 the portal vein. Acetic acid is usually the major short-chain fatty acid in human blood circulation and 81 was found to be a possible energy source for the liver (13, 14). Butyric acid was found to be particularly 82 of benefit for colon health as primal energy source for colonocytes (12). A very recent work by Lv et. 83 al. showed an impact of serum levels from gut microbiota generated butyrate on the muscle mass 84 index in healthy menopausal women (15). Furthermore, there are studies which demonstrate that 85

4

SCFAs directly influence muscle mass *in vivo* (16-18). For example, Gao et al. demonstrated that chronic supplementation with butyrate preserves skeletal muscle in relation to the total body fat mass in rodents when incorporated into a high-fat diet (17). Also, Lahiri et al. clearly demonstrated the influence of gut microbiota on gene expression in muscle tissue and transcription of genes associated with skeletal muscle growth and function in mice (18).

All SCFAs show age related changes (19), but compared to "the big 3" – acetic (C2), propionic (C3) and 91 butyric acid (C4) – valeric (C5) and caproic acid (C6) are commonly present at lower concentrations in 92 feces and the circulation, and have not been considered as SCFAs strictly produced by the microbiota 93 until now (19). However, in a recent article, they were found to be potent class I histone acetylase 94 inhibitors (20). Valeric acid (VA) was further shown to inhibit the growth of *Clostridium difficile* when 95 it was restored by fecal microbiota transplantation (21). In another preclinical study in mice, VA was 96 found to reduce toxic injuries that were caused by radiation (22). However, compared to the other 97 SCFAs, very little is known about the effects of VA on intestinal health and on health in general. 98

Some studies have shown that there is a link between the microbiome and age-related muscle loss, 99 known as the "gut-muscle axis" (23-25). It is known that the pathophysiology of age-related muscle 100 loss could be influenced by gut microbiota through different mechanisms of chronic inflammation and 101 anabolic resistance (26). Loss of muscle mass e.g. with ageing or inactivity could lead to an increased 102 fatty infiltration of the muscle tissue and therefore to an increased amount of intramuscular adipose 103 tissue (IMAT) (27, 28). IMAT is also associated with a loss of muscle function (27). Furthermore, a 104 negative effect of the amount of IMAT on glucose metabolism has been shown and several authors 105 found relations between IMAT in the thigh muscles and different factors of cardiometabolic risk (29-106 32). Moreover, it was suggested by Goodpaster et. al. that too much IMAT may lead to an elevated 107 free fatty acid (FFA) concentration in the skeletal muscles, which could cause a reduction in 108 intramuscular blood flow followed by lower insulin diffusion capacity (33). 109

To achieve an accurate and radiation-free quantification of muscle mass and IMAT, magnet resonance 110 imaging (MRI) is the most suitable method (29, 34, 35). Due to the development of new scanning 111 techniques, examinations can nowadays be carried out in reasonable time (36, 37). 112

In the present study, we investigated a possible relationship between SCFAs, muscle mass and 113 intramuscular adipose tissue in our study cohort of healthy active volunteers. Since other studies have 114 shown associations between the gut microbiome and age-related muscle loss in men (24), we further 115 wanted to investigate sex differences as well as relationships with body composition. Additionally, we 116 compared the measured parameters between information on endurance and strength training. 117

Materials and Methods

119

120

121

118

Subjects.

The included study subjects all gave written informed consent. The study participants were recruited 122 from 12th of April 2018 until the 2nd February of 2019, and the study was approved by the local Ethics 123 Committee of the Medical University Graz; (approval number: EK-Nr. 29-585 ex 16/17). The study had 124 a cross-sectional design and 155 volunteers (78 females and 77 males) were included in the study. 125 Some of the samples and data from our MRI-adipose tissue measurement study have been used and 126 already published (38, 39). We excluded volunteers with known hyperlipidemia, metabolic disorders 127 such as diabetes, and neurological and muscle diseases. Additionally, metallic implants and/or 128 claustrophobia were reasons for study exclusion to MRI examinations. We collected parameters such 129 as the height, weight, waist and hip circumference in every volunteer. We calculated ratios such as the 130 waist/hip ratio and waist/height ratio. 131

The participants was given a questionnaire to note frequency, duration and nature of their sport 132 activities as well as their lifestyle and dietary style (see supplements S1). The training frequency and 133

duration were divided according to different training modes, in both endurance and resistance 134 training. At the time of study inclusion, all subjects were healthy, and no one reported taking any 135 antibiotics.

137

138

Magnetic resonance imaging (MRI) and image processing

We performed MRI examination of the thigh after standardized positioning of a marker using a 3 Tesla 139 magnetic resonance scanner (Siemens MAGNETOM® Prisma, Siemens Healthcare, Erlangen, 140 Germany). The marker enables an exact localization of the measurements by using a standardized 141 method developed by Mueller et al. (40). The MRI protocol consists of a standard 2-Point DIXON 142 Sequence (TR 4.66ms, TE1 1.24ms, TE2 2.47ms, Flip angle 9°, base resolution 288, ISO Voxel Size: 1.4 x 143 1.4x1.4mm, PAT 4).

MRI data were analyzed using FIJI, which is an open-source image-processing package based on 145 ImageJ (41). We used the image slice with the visible marker position for quantitative segmentation. 146 The cross-sectional muscle area (MA) and intramuscular adipose tissue (IMAT) compartment were 147 evaluated separately. The MA and percentage of IMAT in between the MA were calculated (38). Figure 148 1 shows segmentation results for and muscle area. 149

Blood collection and clinical laboratory analysis

Venous blood samples were collected from every subject prior to MRI measurements. The blood 152 samples were collected after a 12 h fasting period. Serum lipid panel contained total blood cholesterol 153 (mg/dL), HDL (mg/dL), LDL (mg/dL), and serum triglycerides (mg/dL). The total cholesterol/HDL 154 quotient was calculated. Serum levels of leptin (ng/ml) were analyzed using an appropriate human 155 ELISA Kit[®] (BioVendor, Czech Republic) according to the manufacturer's instructions. Standards, 156 controls (high and low) and samples were measured in duplicates. The standard curves were calculated 157

150

using the four-parameter algorithm. All blood samples were analyzed in the same laboratory with a 158 standardized protocol using frozen serum (– 80 °C). 159

160

Determination of short chain fatty acids by gas chromatograph-electron impact-mass spectrometer 161 (GC-EI/MS) 162

Propionic acid-d6 was purchased from EQ Laboratories (Augsburg, Germany) and all other chemicals 163 were supplied from Sigma Aldrich (St. Louis, MO, USA). A measure of 10 µl of an internal standard mix 164 was added to 100 μ I of serum samples, resulting in a final concentration of 100 μ M acetic acid-d4, 165 propionic acid-d6, butyric acid-d8, valeric acid-d9 and hexanoic acid-d3 each. Subsequently, 110 μl of 166 methyl tert-butyl ether (MTBE) was added. The mixture was shaken for 10 min and then centrifuged 167 in a lab centrifuge at 2500 rpm. The upper phase was transferred into a GC-MS vial. The injection 168 volume was 1 μ l in splitless mode at 250°C injector temperature. The GC oven was equipped with a 1 169 DB-WAX UI GC-column (30m x 0.25mm ID x 0.25µm film) and an initial oven temperature of 40°C was 170 held for 2 min. Thereafter, it was ramped up to 150°C at a rate of 15°C/ min followed by an increase of 171 5°C/min up to 170°C and an increase of 20°C/min up to 250°C, where the temperature was finally held 172 for 5 min. Helium was used as a carrier gas at a flow rate of 1.3 ml/min. The transfer line temperature 173 was set to 280°C. The mass spectrometer was operated in SIM mode using the following m/z values: 17460, 63, 73, 74, 76, 79 and 80 at their respective retention times. Acetic (C2), propionic (C3), butyric 175 (C4), valeric (C5) and hexanoic (C6) acid were determined by one-point calibration versus their 176 corresponding internal standards. 177

178

179

Statistics

Statistics were performed using SPSS version 27 (IBM). Group differences between males and females 180 in the descriptive evaluation have been performed using Welch's *t*-test. Statistical comparison of 181

parametric continuous subject characteristics was accomplished using the two-sided Student's *t*-test 182 with Pearson's linear correlation coefficients over the whole study population and separated into 183 groups according to sex. The distribution was tested for normality using the Shapiro–Wilk test. A p-184 value <0.05 was considered to be statistically significant. A stepwise multiple linear regression analysis 185 was performed to adjust the relations for age, BMI, training activities and serum lipid panel including 186 Fisher's z-transformation for the Pearson correlation coefficients. 187

188

Results

Subjects

The study had a cross-sectional design including 155 volunteers; 78 females/77 males; age: min 21.4max 76.3 (males 41.65 ± 11.53/mean ± SD, females 45.31 ± 10.41/mean ± SD). Table 1 shows the age, 193 BMI, waist/hip and waist/height ratios, muscle areas and areas of adipose tissue compartments 194 including the ratios of the fat compartments, respectively, and serum levels of SCFAs, as well as the 195 lipid profile of the entire study population. The parameters were indicated for both males and females. 196

The BMI was statistically significantly higher in the male group than in females. The muscle crosssectional area showed significantly higher values in the male group than in females. The percentage of IMAT per MA was significantly lower in the male group. HDL was higher in females. No statistically significant differences were found between the weekly endurance training times in men and women, but men performed significantly longer weekly resistance training units. Comparing the levels of all SCFAs between both sexes, no significant differences were found between men and women (Table 1). 202

- •					
5)	Female (n=)	78)	Male (n=7	7)	p-value
± 11.10	45.31	± 10.41	41.65	± 11.53	0.040*
± 3.12	22.88	± 3.29	24.60	± 2.70	0.001***
± 0.07	0.78	± 0.06	0.86	± 0.07	<0.001***
± 0.05	0.46	± 0.06	0.48	± 0.05	0.009***
± 3395.47	11702.30	± 1486.93	16771.17	± 2818.97	<0.001***
± 0.05	0.89±	± 0.05	0.87±	± 0.05	0.007**
± 0.05	0.08	± 0.05	0.04±	± 0.02	<0.001***
± 8.73	9.15	± 9.20	7.68	± 8.18	0.312
± 32.49	200.18	± 30.15	189.51	± 34.02	0.040*
± 17.78	76.10	± 18.74	61.94	± 13.60	<0.001***
± 30.84	102.74	± 29.37	103.10	± 32.36	0.943
	<pre>± 11.10 ± 3.12 ± 0.07 ± 0.05 ± 3395.47 ± 0.05 ± 0.05 ± 8.73 ± 8.73 ± 32.49 ± 17.78 ± 30.84</pre>	± 11.10 45.31 ± 3.12 22.88 ± 0.07 0.78 ± 0.05 0.46 ± 3395.47 11702.30 ± 0.05 0.89± ± 0.05 0.08 ± 0.05 0.08 ± 11702.30 ± 0.05 0.89± ± 0.05 0.08 ± 10.5 0.08 ± 17.78 76.10 ± 30.84 102.74	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$

Table 1: Descriptive statistics of the study population.

190

medRxiv preprint doi: https://doi.org/10.1101/2023.08.11.23293978; this version posted August 15, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

lt is made available under	а	CC-BY	4.0	International license.	

Triglycerides (mg/dl)	115.56	± 88.95	108.17	± 99.68	122.86	± 76.87	0.306
SCFA							
C2 (µmol/L)	10700.92	± 9583.07	10207.33	± 8810.55	11188.19	± 10239.52	0.523
C3 (µmol/L)	572.33	± 353.33	566.44	± 335.27	578.13	± 372.39	0.838
C4 (μmol/L)	56.51	± 32.43	54.50	± 30.00	58.49	± 34.76	0.446
C5 (μmol/L)	11.77	± 7.83	11.07	± 7.36	12.48	± 8.06	0.257
C6 (µmol/L)	60.52	± 40.72	58.14	± 38.96	62.86	± 42.51	0.472
Sport profile							
Endurance (min/w)	221.20	± 371.15	188.65	± 403.77	253.33	± 335.50	0.280
Resistance (min/w)	87.00	± 105.18	67.18	± 85.88	106.56	± 118.59	0.019*
Endurance (Sessions/w)	2.72	± 2.12	2.59	± 2.22	2.84	± 2.01	0.455
Resistance (Sessions/w)	1.71	± 1.86	1.41	± 1.70	2.01	± 1.97	0.044*

Sex differences were evaluated via t-test. The shown p-values mark significant sex differences (values are reported as mean \pm SD). Intermuscular adipose tissue (IMAT); subcutaneous adipose tissue (SAT); low-density lipoprotein (LDL); high-density lipoprotein (HDL); p < .05 indicated as *, p < .01 indicated as **, p < .001 indicated as ***

203

204

Pearson correlations differ in males vs. females

Table 2 shows the correlation of SCFAs, adipose tissue and muscle tissue segmentation results. The205most interesting observation in this study was a significant correlation of the cross-sectional muscle206area of the mid-thigh with circulating VA (C5) in healthy males (r=0.324/p-value=.004). This association207was not found in females (r=-.030/p-value=.793). The scatterplots of VA versus muscle mass are shown208in Fig.2. No correlation was found between circulating SCFAs and the weekly duration of resistance209training in both males and females.210

Table 2: Pearson correlation results between SCFA serum levels, thigh MA, intermuscular adipose

 tissue segmentation results, and weekly training times.

	Sex	C2	С3	C4	C5	C6
		r	r	r	r	r
Features		p .	р	р	p .	р

medRxiv preprint doi: https://doi.org/10.1101/2023.08.11.23293978; this version posted August 15, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

F + -		-
It is made available under a	CC-BY	4.0 International license
	~~ ~ .	

MA	Male	0.038	0.083	0.149	0.324	0.101
		0.77	0.47	0.19	0.004**	0.38
	Female	0.041	0.078	0.008	-0.030	0.108
		0.73 / 0.96	0.50 / 0.92	0.95 / 0.98	0.79 / 0.95	0.94 / 0.99
IMAT/MA	Male	-0.041	-0.025	-0.054	-0.119	0.099
		0.72 / 0.99	0.83 / 0.97	0.64 / 0.95	0.30 / 0.98	0.39 / 0.93
	Female	-0.124	-0.183	-0.183	-0.109	0.076
		0.28 / 0.99	0.11/>0.99	0.11/0.97	0.35 / 0.93	0.51/0.91
Resistance (min	Male	-0.003	0.095	0.098	0.059	-0.105
w)		0.98 / 0.99	0.41/0.94	0.39 / 0.91	0.61 / 0.96	0.36 / 0.95
	Female	0.041	-0.008	-0.032	-0.031	-0.155
		0.72 / 0.97	0.95 / 0.98	0.78 / 0.98	0.79 / 0.96	0.18 / 0.77
Endurance (min	Male	-0.017	-0.031	0.000	0.112	0.169
w)		0.88 / 0.99	0.79 / 0.96	>0.99 / >0.99	0.33 / 0.95	0.14 / 0.85
	Female	-0.080	-0.035	-0.051	-0.104	-0.077
		0.49/0.91	0.76 / 0.99	0.66 / 0.97	0.37 / 0.92	0.51/0.91

Pearson correlation coefficients r, and corresponding p-values are displayed. Intermuscular adipose tissue (IMAT), ; p < .05 indicated as *, p < .01 indicated as **, p < .001 indicated as ***

	211
	212
Results of the multivariate regression analysis	213
In an additional multivariate regression analysis with VA (C5) as constant, we could show that the	214
relationship between the cross-sectional muscle area and VA in males remains significant. The model	215
was adjusted for age, BMI, endurance and resistance training times and serum lipids. In females, none	216
of the factors are related or influenced the VA levels (Table 3. a, b).	217

Table 3a: Effect of cross-sectional MA, age, body mass index, resistance and endurance training and serum lipid panel on VA levels in men (stepwise inclusion).

			Fstat (p-
Predictor	t-value	Pr(> t)	value)

				adj. R2	8.606
	ß-coefficients			0.091	(0.004**)
Constant		-0.557	0.579		
MA	0.321	2.934	0.004**		
Age	0.034	0.304	0.762		
BMI	-0.162	-1.296	0.199		
Endurance time/week	0.040	0.355	0.723		
Endurance units/week	0.083	0.736	0.464		
Resistance time/week	-0.056	-0.482	0.632		
Resistance units/week	0.072	0.631	0.530		
Cholesterol(mg/dl)	-0.127	-1.157	0.251		
LDL (mg/dl)	-0.090	-0.819	0.451		
HDL (mg/dl)	0.052	0.472	0.638		
Triglycerides (mg/dl)	-0.133	-1.203	0.233		
<u> </u>					

Standardized ß- coefficients, t- values and associated p-values are shown. Dependent variable: VA (C5).

218

 Table 3b: Effect of cross-sectional MA, age, body mass index, resistance and endurance training and

serum lipid panel on VA levels in women (stepwise inclusion).

					Fstat (p-
					value)
				adj. R2	1.186
Predictor	ß-coefficients	t-value	Pr(> t)	0.015	(0.318)
Constant		2.052	0.044		
MA	0.063	0.429	0.669		
Age	0.198	1.383	0.172		
ВМІ	-0.190	-1.191	0.238		
Endurance time/week	-0.018	-0.125	0.901		
Endurance units/week	-0.272	-1.899	0.062		
Resistance time/week	0.162	0.575	0.567		
Resistance units/week	-0.093	-0.351	0.727		
Cholesterol(mg/dl)	-0.102	-0.665	0.509		

HDL (mg/dl)	-0.225	-1.530	0.131
Triglycerides (mg/dl)	0.158	1.139	0.259

Standardized ß- coefficients, t- values and associated p-values are shown. Dependent variable: VA (C5).

When the cross-sectional muscle area was used as the dependent variable in the model, again, VA was	220
found to be a significant influencing factor along with BMI, age, weekly weight training duration, the	221
number of weekly endurance training sessions, and HDL. Again, in the female group, there was no	222
correlation with VA (Table 4. a, b).	223

Table 4a: Effect of VA, age, body mass index, resistance and endurance training and serum lipid panel on cross-sectional muscle area in men (stepwise inclusion).

				adj. R2	Fstat (p-value)				
Predictor	ß-coefficients	t-value	Pr(> t)	0.091	8.606 (0.004**)				
Constant		1.833	0.069						
BMI	0.472	7.020	<0.001***						
Resistance time/week	0.238	3.860	<0.001***						
Endurance units/week	0.237	3.979	<0.001***						
Age	-0.231	3.759	<0.001***						
C5 (VA)	0.150	2.531	0.012*						
HDL (mg/dl)	-0.152	-2.279	0.024*						
Endurance time/week	0.102	0.137	0.706						
Resistance units/week	0.274	-0.092	0.272						
Cholesterol(mg/dl)	0.289	-0.089	0.738						
LDL (mg/dl)	0.285	-0.090	0.708						
Triglycerides (mg/dl)	0.935	-0.007	0.722						
Standardized <i>β</i> - coefficie	Standardized <i>ß</i> - coefficients, t- values and associated <i>p</i> -values are shown. Dependent variable: MA.								

י י. JJ

Table 4b: Effect of VA, age, body mass index, resistance and endurance training and serum lipid panel on cross-sectional muscle area in women (stepwise inclusion).

				adj. R2	Fstat (p-value) 13.438
Predictor	ß-coefficients	t-value	Pr(> t)	0.260	(<0.001***)
Constant		5.818	0.044		
BMI	0.465	4.549	<0.001***		
Resistance time/week	0.250	2.452	0.017**		
C5 (VA)	-0.470	0.459	0.647		
Age	-0.135	-1.291	0.201		
Endurance time/week	0.117	1.067	0.294		
Endurance units/week	0.162	1.599	0.114		
Resistance units/week	-0.125	-0.585	0.560		
Cholesterol(mg/dl)	-0.145	-1.409	0.163		
HDL (mg/dl)	0.153	1.323	0.190		
LDL (mg/dl)	-0.162	-1.483	0.143		
Triglycerides (mg/dl)	-0.157	1.498	0.139		

Standardized ß- coefficients, t- values and associated p-values are shown. Dependent variable: MA.

	225
	226
Discussion	227
Evidence showing the metabolic effects of the physiologically lower concentrated SCFAs VA and CA is	228
still lacking. To our knowledge, we are the first to show a significant association of the cross-sectional	229
muscle area of the thigh with circulating VA. The second interesting observation is that it was only	230

231

found in healthy males. Furthermore, the relationship remained statistically significant in a

the endurance or resistance training time and units per week showed a statistically significant 233 relationship with VA (C5) in the multivariate regression model. 234

The cause-and-effect principle of our observation cannot be clearly answered at this stage. Different 235 underlying pathophysiological mechanisms could explain the influence of the gut microbiome on 236 skeletal muscle metabolism (18, 23). Therefore, we assume, that VA could influence muscle mass. 237

On the other hand, muscle mass may also have an influence on serum levels of VA. Several studies 238 showed that exercise affects muscle mass, and the microbial diversity in the gut was suggested to be 239 increased (42-44), involving mechanisms such as myokine release, increased intestinal transit, or the 240 secretion of neurotransmitters and hormones, including the promotion of an anti-inflammatory state 241 (43-46). Some animal studies using mouse and rat models indicated changes in the gut microbiome 242 with an increase in several short-chain fatty acid (SCFA)-producing bacteria in mice after strength 243 training (47, 48). A recent study on elite athletes indicated that the gut microbiota could influence their 244 training performance. They found that Veillonella atypica was positively associated with increased 245 physical performance by the metabolization of lactate into propionate in these high-performance 246 athletes (49). A longitudinal study in humans describes changes in the gut microbiome after completing 247 an 8-week endurance program (50). Here, no changes were found after an 8-week intervention with 248 strength training. 249

Compared to these studies, we did not observe a significant influence of endurance or resistance 250 training times on VA levels in males in a multilinear regression analysis, but although we did find a 251 significant influence of training interventions on the cross-sectional muscle area. A reason for this 252 could be the recording of our training modalities with a questionnaire, which may be seen as a study 253 limitation in this context. 254

Recent research with mice found an association of gut microbiota dysbiosis with an 255 underrepresentation of species involved in SCFA synthesis and reduced expression of free fatty acid 256 receptors in enteroendocrine cells, leading to a negative effect for the glucose metabolism of skeletal 257

muscle cells (51). Furthermore, a link between insulin sensitivity and circulating SCFAs has been 258 described in human studies (11). In this context, studies demonstrated that the G protein-coupled 259 receptor 41 plays a role in insulin responsiveness and is enhanced by both propionic and valeric acids 260 on glucose uptake shown in 3T3-L1 adipocytes and C2C12 myotubes; furthermore, a valerate-induced 261 increase in basal glucose uptake in C2C12 myotubes was found, suggesting a role for VA in muscle 262 metabolism (52, 53).

Since the amount of intramuscular adipose tissue is also independently associated with insulin 264 resistance, we would have expected a relationship between IMAT/MA and acetic or valeric acid in this 265 context (11, 30, 31), but that was surprisingly not the case. Using the Welch's test, we did not find 266 significant differences in the VA levels between males and females, contrary to other studies (54). 267 Nevertheless, we found an expected difference in the cross-sectional muscle area of the thigh between 268 males and females. 269

However, our observation supports the findings of previous studies that have shown differences in the 270 gut microbiome between sarcopenic and non-sarcopenic male subjects (23, 24). Compared to that 271 study, we included healthy male and active subjects. The prior study, which found a causal effect 272 between gut microbial synthesis of SCFA butyric acid and the appendicular muscle mass in 273 postmenopausal healthy women (15), could not be supported by our results as we did not observe this 274 in our female cohort. Nevertheless, the associations we observed between VA and MA in males suggest 275 that muscle mass influences VA rather than vice versa, as we did not see this observation in females, 276 possibly due to the lower average muscle mass. 277

By now, only some single studies used VA for therapeutical application. One animal study showed VA 278 glyceride ester feeding to chicken broilers. It resulted in a positive influence of aspects of their 279 performance and a reduction in the number of necrotic enteritis incidences (55). Interestingly, valproic 280 acid, a branched SCFA derivate of VA, is already used as a therapeutic agent for spinal muscular atrophy 281 (SMA). Its administration led to an increase in the expression of survival motoneuron (SMN) mRNA (56, 282 57). Furthermore, treatment with valproic acid resulted in an improvement in gross motor functions 283 for SMA patients (57). Whether the intestinally produced valproic acid can interact with SMN protein 284 levels and thereby have effects on, e.g., muscle mass, or what underlying mechanisms could be 285 responsible for the relationship between muscle mass and VA observed in our male cohort are not 286 currently clear and would need further investigation to ascertain. 287

288

There are some other limitations to this study. The sex hormone status was not recorded, which could 289 play an important role in the build-up of muscle mass. Additionally, information about dietary habits 290 or the use of antibiotics and probiotics was not optimally surveyed. Thus, the observed 291 interrelationships should be investigated in further longitudinal studies. Due to the original study 292 design, the gut microbiota compositions were not examined in this cross-sectional study. Further 293 research is planned to examine sex-specific relationships between gut microbiota, enteral and 294 circulating SCFAs, and changes after training interventions. In terms of disadvantages with the 295 recording of sporting activities with a questionnaire, we intend to carry out more precise examinations. 296 Therefore, studies with performance diagnostics could also be carried out in the future. 297

298

In conclusion, we were able to indicate a significant association between VA and thigh muscle mass in 299 healthy males, which, to our knowledge, has not been described before. In relation to our investigation 300 and other studies, we suppose that training interventions, which effect muscle mass could influence 301 the gut microbiome and consecutively VA concentrations. On the other hand, also an influence of VA 302 on muscle mass is possible, as prior studies found an effect of the gut microbiome on muscle 303 metabolism. Nevertheless, our observation establishes a new view on VA, as it possibly has a more 304 important role in energy metabolism than known and could be examined more closely in future 305 studies. 306

Additional	information:	Competing	financial	and	non-financial	interests	are	disclosed	by	all	308
contributing	g authors. This	research rec	eived no e	exterr	nal funding.						309

References

1.	Scuteri A, Laurent S, Cucca F, Cockcroft J, Cunha PG, Manas LR, et al. Metabolic syndrome	312
acros	ss Europe: different clusters of risk factors. Eur J Prev Cardiol. 2015;22(4):486-91.	313
2.	O'Neill S, O'Driscoll L. Metabolic syndrome: a closer look at the growing epidemic and its	314
asso	ciated pathologies. Obes Rev. 2015;16(1):1-12.	315
3.	Yu K, Yu CG, Yin XQ, Wang ZW, Wang XB, Wang LL, et al. Metabolites of gut microbiome are	316
asso	ciated with glucose metabolism in non-diabetic obese adults: a Chinese monozygotic twin study.	317
Diab	etol Metab Syndr. 2021;13(1):106.	318
4.	Saad MJ, Santos A, Prada PO. Linking Gut Microbiota and Inflammation to Obesity and Insulin	319
Resis	stance. Physiology (Bethesda). 2016;31(4):283-93.	320
5.	Tan J, McKenzie C, Potamitis M, Thorburn AN, Mackay CR, Macia L. The role of short-chain fatty	321
acids	in health and disease. Adv Immunol. 2014;121:91-119.	322
6.	Wang Y, Leong LEX, Keating RL, Kanno T, Abell GCJ, Mobegi FM, et al. Opportunistic bacteria	323
confe	er the ability to ferment prebiotic starch in the adult cystic fibrosis gut. Gut Microbes.	324
2019	;10(3):367-81.	325
7.	Higgins JA. Resistant starch: metabolic effects and potential health benefits. J AOAC Int.	326
2004	;87(3):761-8.	327
8.	Wong JM, de Souza R, Kendall CW, Emam A, Jenkins DJ. Colonic health: fermentation and short	328
chair	n fatty acids. J Clin Gastroenterol. 2006;40(3):235-43.	329
9.	Byrne CS, Chambers ES, Morrison DJ, Frost G. The role of short chain fatty acids in appetite	330
regu	lation and energy homeostasis. Int J Obes (Lond). 2015;39(9):1331-8.	331
10.	Mueller NT, Zhang M, Juraschek SP, Miller ER, Appel LJ. Effects of high-fiber diets enriched with	332
carbo	phydrate, protein, or unsaturated fat on circulating short chain fatty acids: results from the	333
Omn	iHeart randomized trial. Am J Clin Nutr. 2020;111(3):545-54.	334
11.	Müller M, Hernández MAG, Goossens GH, Reijnders D, Holst JJ, Jocken JWE, et al. Circulating	335
but r	not faecal short-chain fatty acids are related to insulin sensitivity, lipolysis and GLP-1	336
conc	entrations in humans. Sci Rep. 2019;9(1):12515.	337
12.	Canfora EE, Jocken JW, Blaak EE. Short-chain fatty acids in control of body weight and insulin	338
sensi	itivity. Nat Rev Endocrinol. 2015;11(10):577-91.	339
13.	Roy CC, Kien CL, Bouthillier L, Levy E. Short-chain fatty acids: ready for prime time? Nutr Clin	340
Pract	t. 2006;21(4):351-66.	341
14.	Calder PC. Fatty Acids: Metabolism. In: Caballero B, Finglas PM, Toldrá F, editors. Encyclopedia	342
of Fo	od and Health. Oxford: Academic Press; 2016. p. 632-44.	343
15.	Lv WQ, Lin X, Shen H, Liu HM, Qiu X, Li BY, et al. Human gut microbiome impacts skeletal	344
muso	cle mass via gut microbial synthesis of the short-chain fatty acid butyrate among healthy	345
men	opausal women. J Cachexia Sarcopenia Muscle. 2021.	346

medRxiv preprint doi: https://doi.org/10.1101/2023.08.11.23293978; this version posted August 15, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity.	
It is made available under a CC-BY	4.0 International license .

16. Frampton J, Murphy KG, Frost G, Chambers ES. Short-chain fatty acids as potential regulators of	347
skeletal muscle metabolism and function. Nat Metab. 2020;2(9):840-8.	348
17. Gao Z, Yin J, Zhang J, Ward RE, Martin RJ, Lefevre M, et al. Butyrate improves insulin sensitivity	349
and increases energy expenditure in mice. Diabetes. 2009;58(7):1509-17.	350
18. Lahiri S, Kim H, Garcia-Perez I, Reza MM, Martin KA, Kundu P, et al. The gut microbiota	351
influences skeletal muscle mass and function in mice. Sci Transl Med. 2019;11(502).	352
19. Rios-Covian D, González S, Nogacka AM, Arboleya S, Salazar N, Gueimonde M, et al. An	353
Overview on Fecal Branched Short-Chain Fatty Acids Along Human Life and as Related With Body	354
Mass Index: Associated Dietary and Anthropometric Factors. Frontiers in Microbiology. 2020;11(973).	355
20. Yuille S, Reichardt N, Panda S, Dunbar H, Mulder IE. Human gut bacteria as potent class I	356
histone deacetylase inhibitors in vitro through production of butyric acid and valeric acid. PLoS One.	357
2018;13(7):e0201073.	358
21. McDonald JAK, Mullish BH, Pechlivanis A, Liu Z, Brignardello J, Kao D, et al. Inhibiting Growth of	359
Clostridioides difficile by Restoring Valerate, Produced by the Intestinal Microbiota.	360
Gastroenterology. 2018;155(5):1495-507.e15.	361
22. Li Y, Dong J, Xiao H, Zhang S, Wang B, Cui M, et al. Gut commensal derived-valeric acid protects	362
against radiation injuries. Gut Microbes. 2020;11(4):789-806.	363
23. Ticinesi A, Mancabelli L, Tagliaferri S, Nouvenne A, Milani C, Del Rio D, et al. The Gut-Muscle	364
Axis in Older Subjects with Low Muscle Mass and Performance: A Proof of Concept Study Exploring	365
Fecal Microbiota Composition and Function with Shotgun Metagenomics Sequencing. Int J Mol Sci.	366
2020;21(23).	367
24. Ticinesi A, Lauretani F, Milani C, Nouvenne A, Tana C, Del Rio D, et al. Aging Gut Microbiota at	368
the Cross-Road between Nutrition, Physical Frailty, and Sarcopenia: Is There a Gut–Muscle Axis?	369
Nutrients. 2017;9(12).	370
25. Ticinesi A, Lauretani F, Tana C, Nouvenne A, Ridolo E, Meschi T. Exercise and immune system as	371
modulators of intestinal microbiome: implications for the gut-muscle axis hypothesis. Exerc Immunol	372
Rev. 2019;25:84-95.	373
26. Prokopidis K, Chambers E, Ni Lochlainn M, Witard OC. Mechanisms Linking the Gut-Muscle Axis	374
With Muscle Protein Metabolism and Anabolic Resistance: Implications for Older Adults at Risk of	375
Sarcopenia. Front Physiol. 2021;12:770455.	376
27. Addison O, Marcus RL, Lastayo PC, Ryan AS. Intermuscular fat: a review of the consequences	377
and causes. Int J Endocrinol. 2014;2014:309570.	378
28. Rowshan K, Hadley S, Pham K, Caiozzo V, Lee TQ, Gupta R. Development of fatty atrophy after	379
neurologic and rotator cuff injuries in an animal model of rotator cuff pathology. J Bone Joint Surg	380
Am. 2010;92(13):2270-8.	381
29. Boettcher M, Machann J, Stefan N, Thamer C, Haring HU, Claussen CD, et al. Intermuscular	382
adipose tissue (IMAT): association with other adipose tissue compartments and insulin sensitivity. J	383
Magn Reson Imaging. 2009;29(6):1340-5.	384
30. Gallagher D, Kuznia P, Heshka S, Albu J, Heymsfield SB, Goodpaster B, et al. Adipose tissue in	385
muscle: a novel depot similar in size to visceral adipose tissue. Am J Clin Nutr. 2005;81(4):903-10.	386
31. Yim JE, Heshka S, Albu J, Heymsfield S, Kuznia P. Harris T, et al. Intermuscular adipose tissue	387
rivals visceral adipose tissue in independent associations with cardiovascular risk. Int J Obes (Lond).	388
2007:31(9):1400-5.	389
	207

32. Bergia RE, 3rd, Kim JE, Campbell WW. Differential Relationship between Intermuscular Adipose	390
Depots with Indices of Cardiometabolic Health. Int J Endocrinol. 2018;2018:2751250.	391
33. Goodpaster BH, Krishnaswami S, Harris TB, Katsiaras A, Kritchevsky SB, Simonsick EM, et al.	392
Obesity, regional body fat distribution, and the metabolic syndrome in older men and women. Arch	393
Intern Med. 2005;165(7):777-83.	394
34. Mercuri E, Cini C, Pichiecchio A, Allsop J, Counsell S, Zolkipli Z, et al. Muscle magnetic resonance	395
imaging in patients with congenital muscular dystrophy and Ullrich phenotype. Neuromuscul Disord.	396
2003;13(7-8):554-8.	397
35. Feng X, Luo S, Li J, Yue D, Xi J, Zhu W, et al. Fatty infiltration evaluation and selective pattern	398
characterization of lower limbs in limb-girdle muscular dystrophy type 2A by muscle magnetic	399
resonance imaging. Muscle Nerve. 2018;58(4):536-41.	400
36. Grande FD, Santini F, Herzka DA, Aro MR, Dean CW, Gold GE, et al. Fat-Suppression Techniques	401
for 3-T MR Imaging of the Musculoskeletal System. RadioGraphics. 2014;34(1):217-33.	402
37. Dixon WT. Simple proton spectroscopic imaging. Radiology. 1984;153(1):189-94.	403
38. Hassler EM, Deutschmann H, Almer G, Renner W, Mangge H, Herrmann M, et al. Distribution of	404
subcutaneous and intermuscular fatty tissue of the mid-thigh measured by MRI-A putative indicator	405
of serum adiponectin level and individual factors of cardio-metabolic risk. PLoS One.	406
2021;16(11):e0259952.	407
39. Hassler E, Almer G, Reishofer G, Deutschmann H, Renner W, Herrmann M, et al. Investigation of	408
the Relationship between the Mid_Thigh Adipose Tissue Distribution Measured by MRI and Serum	409
Osteocalcin— A Sex-Based Approach. Nutrients. 2022;14(1).	410
40. Müller W, Fürhapter-Rieger A, Ahammer H, Lohman TG, Meyer NL, Sardinha LB, et al. Relative	411
Body Weight and Standardised Brightness-Mode Ultrasound Measurement of Subcutaneous Fat in	412
Athletes: An International Multicentre Reliability Study, Under the Auspices of the IOC Medical	413
Commission. Sports Med. 2020;50(3):597-614.	414
41. Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, et al. Fiji: an open-	415
source platform for biological-image analysis. Nat Methods. 2012;9(7):676-82.	416
42. Motiani KK, Collado MC, Eskelinen J-J, Virtanen KA, Löyttyniemi E, Salminen S, et al. Exercise	417
Training Modulates Gut Microbiota Profile and Improves Endotoxemia. Med Sci Sports Exerc.	418
2020;52(1):94-104.	419
43. Codella R, Luzi L, Terruzzi I. Exercise has the guts: How physical activity may positively modulate	420
gut microbiota in chronic and immune-based diseases. Dig Liver Dis. 2018;50(4):331-41.	421
44. Aragón-Vela J, Solis-Urra P, Ruiz-Ojeda FJ, Álvarez-Mercado AI, Olivares-Arancibia J, Plaza-Diaz	422
J. Impact of Exercise on Gut Microbiota in Obesity. Nutrients. 2021;13(11).	423
45. Fan Y, Pedersen O. Gut microbiota in human metabolic health and disease. Nature Reviews	424
Microbiology. 2021;19(1):55-71.	425
46. Castellanos N, Diez GG, Antúnez-Almagro C, Bressa C, Bailén M, González-Soltero R, et al. Key	426
Bacteria in the Gut Microbiota Network for the Transition between Sedentary and Active Lifestyle.	427
Microorganisms. 2020;8(5):785.	428
47. Chen H, Shen L, Liu Y, Ma X, Long L, Ma X, et al. Strength Exercise Confers Protection in Central	429
Nervous System Autoimmunity by Altering the Gut Microbiota. Front Immunol. 2021;12:628629.	430
48. Castro AP, Silva KKS, Medeiros CSA, Alves F, Araujo RC, Almeida JA. Effects of 12 weeks of	431
resistance training on rat gut microbiota composition. J Exp Biol. 2021;224(12).	432

49. Scheiman J, Luber JM, Chavkin TA, MacDonald T, Tung A, Pham L-D, et al. Meta-omics analysis 433 of elite athletes identifies a performance-enhancing microbe that functions via lactate metabolism. 434 Nature Medicine. 2019;25(7):1104-9. 435 Bycura D, Santos AC, Shiffer A, Kyman S, Winfree K, Sutliffe J, et al. Impact of Different Exercise 50. 436 Modalities on the Human Gut Microbiome. Sports (Basel). 2021;9(2). 437 51. Nay K, Jollet M, Goustard B, Baati N, Vernus B, Pontones M, et al. Gut bacteria are critical for 438 optimal muscle function: a potential link with glucose homeostasis. Am J Physiol Endocrinol Metab. 439 2019;317(1):E158-e71. 440 52. Han JH, Kim IS, Jung SH, Lee SG, Son HY, Myung CS. The effects of propionate and valerate on 441 insulin responsiveness for glucose uptake in 3T3-L1 adipocytes and C2C12 myotubes via G protein-442 coupled receptor 41. PLoS One. 2014;9(4):e95268. 443 53. Brown AJ, Goldsworthy SM, Barnes AA, Eilert MM, Tcheang L, Daniels D, et al. The Orphan G 444 protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain 445 carboxylic acids. J Biol Chem. 2003;278(13):11312-9. 446 54. Jakobsdottir G, Bjerregaard JH, Skovbjerg H, Nyman M. Fasting serum concentration of short-447 chain fatty acids in subjects with microscopic colitis and celiac disease: no difference compared with 448 controls, but between genders. Scand J Gastroenterol. 2013;48(6):696-701. 449 Onrust L, Van Driessche K, Ducatelle R, Schwarzer K, Haesebrouck F, Van Immerseel F. Valeric 55. 450 acid glyceride esters in feed promote broiler performance and reduce the incidence of necrotic 451 enteritis. Poult Sci. 2018;97(7):2303-11. 452 56. Wadman RI, van der Pol WL, Bosboom WM, Asselman FL, van den Berg LH, lannaccone ST, et al. 453 Drug treatment for spinal muscular atrophy types II and III. Cochrane Database Syst Rev. 454 2020;1(1):Cd006282. 455 57. Elshafay A, Hieu TH, Doheim MF, Kassem MAM, Eldoadoa MF, Holloway SK, et al. Efficacy and 456 Safety of Valproic Acid for Spinal Muscular Atrophy: A Systematic Review and Meta-Analysis. CNS 457 Drugs. 2019;33(3):239-50. 458

459

460

Figure legends:

Fig.1. DIXON-MRI images of the mid-thigh. The cross-sectional muscle area was calculated from the	464
water images (A) and the adipose tissue compartments were segmented from the fat images (B).	465

466

Fig. 2.a. Scatterplot of the correlations between valeric acid (VA) and muscle area (MA) including	467
regression line in males	468
	469
Fig. 2.b	470
Scatterplot of the correlations between valeric acid (VA) and muscle area (MA) including regression	471
line in females.	472



Figure 1

Males: Valeric Acid versus MA



Figure 2a

Females: Valeric Acid versus MA



Figure 2b